Zoledronic acid improves clinical outcomes when administered before onset of bone pain in patients with prostate cancer Academic Article uri icon

Overview

MeSH Major

  • Bone Density Conservation Agents
  • Bone Neoplasms
  • Diphosphonates
  • Imidazoles
  • Pain
  • Prostatic Neoplasms

abstract

  • ZOL reduced bone pain and SREs compared with placebo in patients with bone metastases from castration-resistant prostate cancer, irrespective of the baseline pain status, and appeared more efficacious when initiated before the onset of pain.

publication date

  • November 2010

Research

keywords

  • Academic Article

Identity

Language

  • eng

Digital Object Identifier (DOI)

  • 10.1016/j.urology.2010.05.026

PubMed ID

  • 21056263

Additional Document Info

start page

  • 1175

end page

  • 81

volume

  • 76

number

  • 5